Jefferies Financial Group Reiterates “Buy” Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “buy” rating restated by research analysts at Jefferies Financial Group in a research report issued on Wednesday, Marketbeat reports. They currently have a GBX 2,100 price objective on the stock. Jefferies Financial Group’s price objective indicates a potential upside of 10.37% from the company’s previous close.

A number of other brokerages have also issued reports on GSK. JPMorgan Chase & Co. increased their price target on GSK from GBX 1,400 to GBX 1,500 and gave the stock an “underweight” rating in a research note on Friday, November 7th. Berenberg Bank increased their target price on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research report on Monday, November 24th. Finally, Shore Capital reissued a “buy” rating on shares of GSK in a research note on Thursday. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of GBX 1,762.

GSK Stock Performance

LON:GSK opened at GBX 1,902.75 on Wednesday. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The stock has a 50-day simple moving average of GBX 1,807.64 and a two-hundred day simple moving average of GBX 1,597.30. The firm has a market capitalization of £76.76 billion, a PE ratio of 14.31, a P/E/G ratio of 1.24 and a beta of 0.31. GSK has a 52-week low of GBX 1,242.50 and a 52-week high of GBX 1,909.73.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, October 29th. The company reported GBX 55 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Analysts forecast that GSK will post 175.980975 EPS for the current year.

Insider Activity

In other news, insider Jonathan Symonds bought 1,650 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were bought at an average cost of GBX 1,810 per share, for a total transaction of £29,865. Also, insider Wendy Becker purchased 441 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were purchased at an average cost of GBX 1,809 per share, with a total value of £7,977.69. Insiders own 0.20% of the company’s stock.

Trending Headlines about GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Bepirovirsen shows promising results in chronic hepatitis B trials, hitting study goals in two trials — a potential long-term commercial opportunity if further development/approval proceeds. GSK’s bepirovirsen shows promising results in chronic hepatitis B trials
• Positive Sentiment: Shingrix advances: European Commission approval for a prefilled syringe format and a separate approval to present Shingrix data — supports ongoing sales momentum and product lifecycle management for an important vaccine franchise. GSK’s Shingrix prefilled syringe receives European Commission approval
• Positive Sentiment: Japan’s MHLW approves Exdensur — a regulatory win that expands GSK’s marketed product base and supports near‑term revenue in Japan. GSK announces approval of Exdensur by Japan’s MHLW
• Positive Sentiment: Jefferies and Shore Capital reaffirm buy ratings (Jefferies sets a GBX 2,100 price target) — positive analyst support could bolster investor interest and help sustain upside momentum. Broker ratings (Jefferies, Shore Capital)
• Neutral Sentiment: Valuation review after strong 1‑year shareholder returns — useful context for investors weighing current price versus fundamentals, not an immediate catalyst. GSK valuation check
• Neutral Sentiment: Real estate transaction: vacant former GSK building sold for $52M — non-operational corporate real estate news with limited impact on core pharmaceuticals business. Vacant former GSK building at the Navy Yard sells for $52M
• Negative Sentiment: JPMorgan reaffirmed an “underweight” rating — a high-profile negative analyst stance that can pressure sentiment and cap upside. Broker ratings (JPMorgan)
• Negative Sentiment: Barclays downgraded GSK — another downgrade adding to mixed broker views and raising near‑term downside risk from sentiment-driven selling. Barclays downgrades GSK

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.